SCHEMBL304000

SCHEMBL304000

Cc1cc2c(cc1-c1cnn(C)c1)NCCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
ATM Q13315 1/20 0.40
BRD4 O60885 1/20 0.40
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
INCENP Q9NQS7 1/20 0.36
TPX2 Q9ULW0 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.35
LRRK2 Q5S007 3/20 0.35
PRKCI P41743 1/20 0.34
PIK3CA P42336 1/20 0.34
TTK P33981 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303897 0.85 PIK3CA (0.43) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL17799485 0.80 CREBBP (0.43) BRD4CREBBP
SCHEMBL17799535 0.80 BRD4 (0.38) ALDH1A1GAAHSD17B10MAPTBRD4
SCHEMBL30023540 0.80 CREBBP (0.43) BRD4CREBBP
SCHEMBL17799353 0.80 PDE3B (0.46) ALDH1A1GAAHSD17B10MAPTBRD4
SCHEMBL23930118 0.78 AXL (0.43) ALDH1A1GAAHSD17B10MAPTBRD4
SCHEMBL304543 0.78 BRD4 (0.53) ALDH1A1GAAHSD17B10MAPTBRD4
SCHEMBL30480844 0.77 PIM1 (0.48) MAPTAURKBLRRK2PIM1JAK1
SCHEMBL31496095 0.75 ATM (0.39) ATMBRD4AURKBAURKAINCENP
SCHEMBL11342856 0.73 ALDH1A1 (0.61) ALDH1A1GAAHSD17B10MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093238-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-01-10 US disclosed
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors JAK1, MTOR, MOK ALDH1A1 1714/4885GAA 1343/4885HSD17B10 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.